Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 264

1.

mRECIST for HCC: Performance and novel refinements.

Llovet JM, Lencioni R.

J Hepatol. 2020 Feb;72(2):288-306. doi: 10.1016/j.jhep.2019.09.026. Review.

PMID:
31954493
2.

Milestones in the pathogenesis and management of primary liver cancer.

Nault JC, Cheng AL, Sangro B, Llovet JM.

J Hepatol. 2020 Feb;72(2):209-214. doi: 10.1016/j.jhep.2019.11.006. No abstract available.

PMID:
31954486
3.

Intratumoral heterogeneity and clonal evolution in liver cancer.

Losic B, Craig AJ, Villacorta-Martin C, Martins-Filho SN, Akers N, Chen X, Ahsen ME, von Felden J, Labgaa I, DʹAvola D, Allette K, Lira SA, Furtado GC, Garcia-Lezana T, Restrepo P, Stueck A, Ward SC, Fiel MI, Hiotis SP, Gunasekaran G, Sia D, Schadt EE, Sebra R, Schwartz M, Llovet JM, Thung S, Stolovitzky G, Villanueva A.

Nat Commun. 2020 Jan 15;11(1):291. doi: 10.1038/s41467-019-14050-z.

4.

CNApp, a tool for the quantification of copy number alterations and integrative analysis revealing clinical implications.

Franch-Expósito S, Bassaganyas L, Vila-Casadesús M, Hernández-Illán E, Esteban-Fabró R, Díaz-Gay M, Lozano JJ, Castells A, Llovet JM, Castellvi-Bel S, Camps J.

Elife. 2020 Jan 15;9. pii: e50267. doi: 10.7554/eLife.50267. [Epub ahead of print]

5.

R-spondin 2 Drives Liver Tumor Development in a Yes-Associated Protein-Dependent Manner.

Conboy CB, Vélez-Reyes GL, Tschida BR, Hu H, Kaufmann G, Koes N, Keller B, Alsinet C, Cornellà H, Pinyol R, Abrahante JE, Temiz NA, Linden MA, Amin K, Kuka TP, Keng VW, Llovet JM, Starr TK, Largaespada DA.

Hepatol Commun. 2019 Sep 3;3(11):1496-1509. doi: 10.1002/hep4.1422. eCollection 2019 Nov.

6.

First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma.

Kim RD, Sarker D, Meyer T, Yau T, Macarulla T, Park JW, Choo SP, Hollebecque A, Sung MW, Lim HY, Mazzaferro V, Trojan J, Zhu AX, Yoon JH, Sharma S, Lin ZZ, Chan SL, Faivre S, Feun LG, Yen CJ, Dufour JF, Palmer DH, Llovet JM, Manoogian M, Tugnait M, Stransky N, Hagel M, Kohl NE, Lengauer C, Sherwin CA, Schmidt-Kittler O, Hoeflich KP, Shi H, Wolf BB, Kang YK.

Cancer Discov. 2019 Dec;9(12):1696-1707. doi: 10.1158/2159-8290.CD-19-0555. Epub 2019 Oct 1.

PMID:
31575541
7.

New Drugs Effective in the Systemic Treatment of Hepatocellular Carcinoma.

Montironi C, Montal R, Llovet JM.

Clin Liver Dis (Hoboken). 2019 Sep 2;14(2):56-61. doi: 10.1002/cld.796. eCollection 2019 Aug. Review. No abstract available.

8.

Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma.

Yarchoan M, Agarwal P, Villanueva A, Rao S, Dawson LA, Llovet JM, Finn RS, Groopman JD, El-Serag HB, Monga SP, Wang XW, Karin M, Schwartz RE, Tanabe KK, Roberts LR, Gunaratne PH, Tsung A, Brown KA, Lawrence TS, Salem R, Singal AG, Kim AK, Rabiee A, Resar L, Hoshida Y, He AR, Ghoshal K, Ryan PB, Jaffee EM, Guha C, Mishra L, Coleman CN, Ahmed MM.

Cancer Res. 2019 Sep 1;79(17):4326-4330. doi: 10.1158/0008-5472.CAN-19-0803. Erratum in: Cancer Res. 2019 Nov 15;79(22):5897.

9.

Liver transplant for hepatocellular carcinoma in the United States: Evolving trends over the last three decades.

Puigvehí M, Hashim D, Haber PK, Dinani A, Schiano TD, Asgharpour A, Kushner T, Kakked G, Tabrizian P, Schwartz M, Gurakar A, Dieterich D, Boffetta P, Friedman SL, Llovet JM, Saberi B.

Am J Transplant. 2020 Jan;20(1):220-230. doi: 10.1111/ajt.15576. Epub 2019 Oct 11.

PMID:
31437349
10.

Biology and significance of alpha-fetoprotein in hepatocellular carcinoma.

Galle PR, Foerster F, Kudo M, Chan SL, Llovet JM, Qin S, Schelman WR, Chintharlapalli S, Abada PB, Sherman M, Zhu AX.

Liver Int. 2019 Dec;39(12):2214-2229. doi: 10.1111/liv.14223. Epub 2019 Sep 11. Review.

PMID:
31436873
11.

An Immune Gene Expression Signature Associated With Development of Human Hepatocellular Carcinoma Identifies Mice That Respond to Chemopreventive Agents.

Moeini A, Torrecilla S, Tovar V, Montironi C, Andreu-Oller C, Peix J, Higuera M, Pfister D, Ramadori P, Pinyol R, Solé M, Heikenwälder M, Friedman SL, Sia D, Llovet JM.

Gastroenterology. 2019 Nov;157(5):1383-1397.e11. doi: 10.1053/j.gastro.2019.07.028. Epub 2019 Jul 22.

PMID:
31344396
12.

Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials.

Montal R, Andreu-Oller C, Bassaganyas L, Esteban-Fabró R, Moran S, Montironi C, Moeini A, Pinyol R, Peix J, Cabellos L, Villanueva A, Sia D, Mazzaferro V, Esteller M, Llovet JM.

Br J Cancer. 2019 Aug;121(4):340-343. doi: 10.1038/s41416-019-0513-7. Epub 2019 Jul 9.

PMID:
31285588
13.

Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma.

Nault JC, Martin Y, Caruso S, Hirsch TZ, Bayard Q, Calderaro J, Charpy C, Copie-Bergman C, Ziol M, Bioulac-Sage P, Couchy G, Blanc JF, Nahon P, Amaddeo G, Ganne-Carrie N, Morcrette G, Chiche L, Duvoux C, Faivre S, Laurent A, Imbeaud S, Rebouissou S, Llovet JM, Seror O, Letouzé E, Zucman-Rossi J.

Hepatology. 2020 Jan;71(1):164-182. doi: 10.1002/hep.30811. Epub 2019 Aug 12.

PMID:
31206197
14.

β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma.

Ruiz de Galarreta M, Bresnahan E, Molina-Sánchez P, Lindblad KE, Maier B, Sia D, Puigvehi M, Miguela V, Casanova-Acebes M, Dhainaut M, Villacorta-Martin C, Singhi AD, Moghe A, von Felden J, Tal Grinspan L, Wang S, Kamphorst AO, Monga SP, Brown BD, Villanueva A, Llovet JM, Merad M, Lujambio A.

Cancer Discov. 2019 Aug;9(8):1124-1141. doi: 10.1158/2159-8290.CD-19-0074. Epub 2019 Jun 11.

PMID:
31186238
15.

Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival.

Llovet JM, Montal R, Villanueva A.

J Hepatol. 2019 Jun;70(6):1262-1277. doi: 10.1016/j.jhep.2019.01.028. Epub 2019 Mar 31. Review.

PMID:
30943423
16.

Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of α-fetoprotein.

Zhu AX, Finn RS, Galle PR, Llovet JM, Kudo M.

Lancet Oncol. 2019 Apr;20(4):e191. doi: 10.1016/S1470-2045(19)30165-2. No abstract available.

PMID:
30942178
17.

Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer.

Malehmir M, Pfister D, Gallage S, Szydlowska M, Inverso D, Kotsiliti E, Leone V, Peiseler M, Surewaard BGJ, Rath D, Ali A, Wolf MJ, Drescher H, Healy ME, Dauch D, Kroy D, Krenkel O, Kohlhepp M, Engleitner T, Olkus A, Sijmonsma T, Volz J, Deppermann C, Stegner D, Helbling P, Nombela-Arrieta C, Rafiei A, Hinterleitner M, Rall M, Baku F, Borst O, Wilson CL, Leslie J, O'Connor T, Weston CJ, Adams DH, Sheriff L, Teijeiro A, Prinz M, Bogeska R, Anstee N, Bongers MN, Notohamiprodjo M, Geisler T, Withers DJ, Ware J, Mann DA, Augustin HG, Vegiopoulos A, Milsom MD, Rose AJ, Lalor PF, Llovet JM, Pinyol R, Tacke F, Rad R, Matter M, Djouder N, Kubes P, Knolle PA, Unger K, Zender L, Nieswandt B, Gawaz M, Weber A, Heikenwalder M.

Nat Med. 2019 Apr;25(4):641-655. doi: 10.1038/s41591-019-0379-5. Epub 2019 Apr 1.

18.

Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma.

Teufel M, Seidel H, Köchert K, Meinhardt G, Finn RS, Llovet JM, Bruix J.

Gastroenterology. 2019 May;156(6):1731-1741. doi: 10.1053/j.gastro.2019.01.261. Epub 2019 Feb 6.

19.

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, Schirmacher P, Verslype C, Zech CJ, Arnold D, Martinelli E.

Ann Oncol. 2019 May 1;30(5):871-873. doi: 10.1093/annonc/mdy510. No abstract available.

PMID:
30715202
20.

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, Rau KM, Motomura K, Ohno I, Merle P, Daniele B, Shin DB, Gerken G, Borg C, Hiriart JB, Okusaka T, Morimoto M, Hsu Y, Abada PB, Kudo M; REACH-2 study investigators.

Lancet Oncol. 2019 Feb;20(2):282-296. doi: 10.1016/S1470-2045(18)30937-9. Epub 2019 Jan 18.

PMID:
30665869
21.

Immune Exclusion-Wnt/CTNNB1 Class Predicts Resistance to Immunotherapies in HCC.

Pinyol R, Sia D, Llovet JM.

Clin Cancer Res. 2019 Apr 1;25(7):2021-2023. doi: 10.1158/1078-0432.CCR-18-3778. Epub 2019 Jan 7.

PMID:
30617138
22.

Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types.

Paré L, Pascual T, Seguí E, Teixidó C, Gonzalez-Cao M, Galván P, Rodríguez A, González B, Cuatrecasas M, Pineda E, Torné A, Crespo G, Martin-Algarra S, Pérez-Ruiz E, Reig Ò, Viladot M, Font C, Adamo B, Vidal M, Gaba L, Muñoz M, Victoria I, Ruiz G, Viñolas N, Mellado B, Maurel J, Garcia-Corbacho J, Molina-Vila MÁ, Juan M, Llovet JM, Reguart N, Arance A, Prat A.

Ann Oncol. 2018 Oct 1;29(10):2121-2128. doi: 10.1093/annonc/mdy335.

23.

Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial.

Pinyol R, Montal R, Bassaganyas L, Sia D, Takayama T, Chau GY, Mazzaferro V, Roayaie S, Lee HC, Kokudo N, Zhang Z, Torrecilla S, Moeini A, Rodriguez-Carunchio L, Gane E, Verslype C, Croitoru AE, Cillo U, de la Mata M, Lupo L, Strasser S, Park JW, Camps J, Solé M, Thung SN, Villanueva A, Pena C, Meinhardt G, Bruix J, Llovet JM.

Gut. 2019 Jun;68(6):1065-1075. doi: 10.1136/gutjnl-2018-316408. Epub 2018 Aug 14.

24.

Molecular therapies and precision medicine for hepatocellular carcinoma.

Llovet JM, Montal R, Sia D, Finn RS.

Nat Rev Clin Oncol. 2018 Oct;15(10):599-616. doi: 10.1038/s41571-018-0073-4. Review.

PMID:
30061739
25.

Liver Cancer Disparities in New York City: A Neighborhood View of Risk and Harm Reduction Factors.

Kamath GR, Taioli E, N Egorova N, Llovet JM, Perumalswami PV, Weiss JJ, Schwartz M, Ewala S, Bickell NA.

Front Oncol. 2018 Jun 14;8:220. doi: 10.3389/fonc.2018.00220. eCollection 2018.

26.

Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma.

Lim HY, Merle P, Weiss KH, Yau T, Ross P, Mazzaferro V, Blanc JF, Ma YT, Yen CJ, Kocsis J, Choo SP, Sukeepaisarnjaroen W, Gérolami R, Dufour JF, Gane EJ, Ryoo BY, Peck-Radosavljevic M, Dao T, Yeo W, Lamlertthon W, Thongsawat S, Teufel M, Roth K, Reis D, Childs BH, Krissel H, Llovet JM.

Clin Cancer Res. 2018 Oct 1;24(19):4650-4661. doi: 10.1158/1078-0432.CCR-17-3588. Epub 2018 Jun 27.

27.

A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma.

Labgaa I, Villacorta-Martin C, D'Avola D, Craig AJ, von Felden J, Martins-Filho SN, Sia D, Stueck A, Ward SC, Fiel MI, Mahajan M, Tabrizian P, Thung SN, Ang C, Friedman SL, Llovet JM, Schwartz M, Villanueva A.

Oncogene. 2018 Jul;37(27):3740-3752. doi: 10.1038/s41388-018-0206-3. Epub 2018 Apr 9.

28.

Negative phase 3 study of 90Y microspheres versus sorafenib in HCC.

Llovet JM, Finn RS.

Lancet Oncol. 2018 Feb;19(2):e69. doi: 10.1016/S1470-2045(18)30025-1. No abstract available.

PMID:
29413470
29.

Beta-catenin cleavage enhances transcriptional activation.

Goretsky T, Bradford EM, Ye Q, Lamping OF, Vanagunas T, Moyer MP, Keller PC, Sinh P, Llovet JM, Gao T, She QB, Li L, Barrett TA.

Sci Rep. 2018 Jan 12;8(1):671. doi: 10.1038/s41598-017-18421-8.

30.

Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended criteria).

Llovet JM, Pavel M, Rimola J, Diaz MA, Colmenero J, Saavedra-Perez D, Fondevila C, Ayuso C, Fuster J, Ginès P, Bruix J, Garcia-Valdecasas JC.

Liver Transpl. 2018 Mar;24(3):369-379. doi: 10.1002/lt.24977.

31.

Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma.

Torrecilla S, Sia D, Harrington AN, Zhang Z, Cabellos L, Cornella H, Moeini A, Camprecios G, Leow WQ, Fiel MI, Hao K, Bassaganyas L, Mahajan M, Thung SN, Villanueva A, Florman S, Schwartz ME, Llovet JM.

J Hepatol. 2017 Dec;67(6):1222-1231. doi: 10.1016/j.jhep.2017.08.013. Epub 2017 Aug 24.

32.

Liver cancer: Translating '-omics' results into precision medicine for hepatocellular carcinoma.

Sia D, Llovet JM.

Nat Rev Gastroenterol Hepatol. 2017 Oct;14(10):571-572. doi: 10.1038/nrgastro.2017.103. Epub 2017 Aug 2. No abstract available.

PMID:
28765583
33.

Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features.

Sia D, Jiao Y, Martinez-Quetglas I, Kuchuk O, Villacorta-Martin C, Castro de Moura M, Putra J, Camprecios G, Bassaganyas L, Akers N, Losic B, Waxman S, Thung SN, Mazzaferro V, Esteller M, Friedman SL, Schwartz M, Villanueva A, Llovet JM.

Gastroenterology. 2017 Sep;153(3):812-826. doi: 10.1053/j.gastro.2017.06.007. Epub 2017 Jun 15.

34.

Imaging-based surrogate markers of transcriptome subclasses and signatures in hepatocellular carcinoma: preliminary results.

Taouli B, Hoshida Y, Kakite S, Chen X, Tan PS, Sun X, Kihira S, Kojima K, Toffanin S, Fiel MI, Hirschfield H, Wagner M, Llovet JM.

Eur Radiol. 2017 Nov;27(11):4472-4481. doi: 10.1007/s00330-017-4844-6. Epub 2017 Apr 24.

35.

Reply to: "mRECIST for systemic therapies: More evidence is required before recommendations could be made".

Montal R, Lencioni R, Llovet JM.

J Hepatol. 2017 Jul;67(1):196-197. doi: 10.1016/j.jhep.2017.03.004. Epub 2017 Mar 16. No abstract available.

PMID:
28315709
36.

Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC.

Lencioni R, Montal R, Torres F, Park JW, Decaens T, Raoul JL, Kudo M, Chang C, Ríos J, Boige V, Assenat E, Kang YK, Lim HY, Walters I, Llovet JM.

J Hepatol. 2017 Jun;66(6):1166-1172. doi: 10.1016/j.jhep.2017.01.012. Epub 2017 Jan 26.

37.

Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.

Moeini A, Sia D, Zhang Z, Camprecios G, Stueck A, Dong H, Montal R, Torrens L, Martinez-Quetglas I, Fiel MI, Hao K, Villanueva A, Thung SN, Schwartz ME, Llovet JM.

J Hepatol. 2017 May;66(5):952-961. doi: 10.1016/j.jhep.2017.01.010. Epub 2017 Jan 23.

38.

Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis.

Sia D, Villanueva A, Friedman SL, Llovet JM.

Gastroenterology. 2017 Mar;152(4):745-761. doi: 10.1053/j.gastro.2016.11.048. Epub 2016 Dec 30. Review.

39.

Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition.

Nakagawa S, Wei L, Song WM, Higashi T, Ghoshal S, Kim RS, Bian CB, Yamada S, Sun X, Venkatesh A, Goossens N, Bain G, Lauwers GY, Koh AP, El-Abtah M, Ahmad NB, Hoshida H, Erstad DJ, Gunasekaran G, Lee Y, Yu ML, Chuang WL, Dai CY, Kobayashi M, Kumada H, Beppu T, Baba H, Mahajan M, Nair VD, Lanuti M, Villanueva A, Sangiovanni A, Iavarone M, Colombo M, Llovet JM, Subramanian A, Tager AM, Friedman SL, Baumert TF, Schwarz ME, Chung RT, Tanabe KK, Zhang B, Fuchs BC, Hoshida Y; Precision Liver Cancer Prevention Consortium.

Cancer Cell. 2016 Dec 12;30(6):879-890. doi: 10.1016/j.ccell.2016.11.004.

40.

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.

Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G; RESORCE Investigators.

Lancet. 2017 Jan 7;389(10064):56-66. doi: 10.1016/S0140-6736(16)32453-9. Epub 2016 Dec 6. Erratum in: Lancet. 2017 Jan 7;389(10064):36.

PMID:
27932229
41.

Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma.

Bollard J, Miguela V, Ruiz de Galarreta M, Venkatesh A, Bian CB, Roberto MP, Tovar V, Sia D, Molina-Sánchez P, Nguyen CB, Nakagawa S, Llovet JM, Hoshida Y, Lujambio A.

Gut. 2017 Jul;66(7):1286-1296. doi: 10.1136/gutjnl-2016-312268. Epub 2016 Nov 14.

42.

IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.

Martinez-Quetglas I, Pinyol R, Dauch D, Torrecilla S, Tovar V, Moeini A, Alsinet C, Portela A, Rodriguez-Carunchio L, Solé M, Lujambio A, Villanueva A, Thung S, Esteller M, Zender L, Llovet JM.

Gastroenterology. 2016 Dec;151(6):1192-1205. doi: 10.1053/j.gastro.2016.09.001. Epub 2016 Sep 7.

43.

Liver cancer: Effect of HCV clearance with direct-acting antiviral agents on HCC.

Llovet JM, Villanueva A.

Nat Rev Gastroenterol Hepatol. 2016 Oct;13(10):561-2. doi: 10.1038/nrgastro.2016.140. Epub 2016 Sep 1. No abstract available.

PMID:
27580683
44.

Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis.

Moran S, Martínez-Cardús A, Sayols S, Musulén E, Balañá C, Estival-Gonzalez A, Moutinho C, Heyn H, Diaz-Lagares A, de Moura MC, Stella GM, Comoglio PM, Ruiz-Miró M, Matias-Guiu X, Pazo-Cid R, Antón A, Lopez-Lopez R, Soler G, Longo F, Guerra I, Fernandez S, Assenov Y, Plass C, Morales R, Carles J, Bowtell D, Mileshkin L, Sia D, Tothill R, Tabernero J, Llovet JM, Esteller M.

Lancet Oncol. 2016 Oct;17(10):1386-1395. doi: 10.1016/S1470-2045(16)30297-2. Epub 2016 Aug 27.

PMID:
27575023
45.

Hepatocellular carcinoma.

Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G.

Nat Rev Dis Primers. 2016 Apr 14;2:16018. doi: 10.1038/nrdp.2016.18. Review.

46.

[Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH].

Forner A, Reig M, Varela M, Burrel M, Feliu J, Briceño J, Sastre J, Martí-Bonmati L, Llovet JM, Bilbao JI, Sangro B, Pardo F, Ayuso C, Bru C, Tabernero J, Bruix J.

Med Clin (Barc). 2016 Jun 3;146(11):511.e1-511.e22. doi: 10.1016/j.medcli.2016.01.028. Epub 2016 Mar 11. Spanish.

PMID:
26971984
47.

Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.

Lencioni R, Llovet JM, Han G, Tak WY, Yang J, Guglielmi A, Paik SW, Reig M, Kim DY, Chau GY, Luca A, Del Arbol LR, Leberre MA, Niu W, Nicholson K, Meinhardt G, Bruix J.

J Hepatol. 2016 May;64(5):1090-1098. doi: 10.1016/j.jhep.2016.01.012. Epub 2016 Jan 22.

PMID:
26809111
48.

Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma.

Tovar V, Cornella H, Moeini A, Vidal S, Hoshida Y, Sia D, Peix J, Cabellos L, Alsinet C, Torrecilla S, Martinez-Quetglas I, Lozano JJ, Desbois-Mouthon C, Solé M, Domingo-Domenech J, Villanueva A, Llovet JM.

Gut. 2017 Mar;66(3):530-540. doi: 10.1136/gutjnl-2015-309501. Epub 2015 Dec 11.

49.

Corrigendum: Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer.

Saha SK, Parachoniak CA, Ghanta KS, Fitamant J, Ross KN, Najem MS, Gurumurthy S, Akbay EA, Sia D, Cornella H, Miltiadous O, Walesky C, Deshpande V, Zhu AX, Hezel AF, Yen KE, Straley KS, Travins J, Popovici-Muller J, Gliser C, Ferrone CR, Apte U, Llovet JM, Wong KK, Ramaswamy S, Bardeesy N.

Nature. 2015 Dec 3;528(7580):152. doi: 10.1038/nature16136. Epub 2015 Nov 18. No abstract available.

PMID:
26580013
50.

Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma.

Moeini A, Sia D, Bardeesy N, Mazzaferro V, Llovet JM.

Clin Cancer Res. 2016 Jan 15;22(2):291-300. doi: 10.1158/1078-0432.CCR-14-3296. Epub 2015 Sep 24. Review.

Supplemental Content

Loading ...
Support Center